Filtering by: Buprenorphine
Jan
28
12:00 PM12:00
Buprenorphine, Implementation Science, Misinformation, Rural Health, Stigma

CDIAS PSMG: Berkely Franz

The Buprenorphine Prescribing Support Program for Rural Primary Care

Berkely Franz, PhD
Heritage College of Osteopathic Medicine

ABSTRACT:
Buprenorphine is a critical tool to prevent overdose and infectious disease transmission in people with opioid use disorder, but it is difficult to access in rural areas. A promising solution is to engage rural primary care professionals. But the willingness of primary care professionals to prescribe this medication presents a vexing implementation science challenge—fewer than 8% of PCPs have ever prescribed buprenorphine. Stigma is a well-accepted prescribing barrier, but few implementation studies have focused on measuring and addressing the different types of stigma that matter for implementation. To address these barriers, we developed, iterated, refined, and pilot tested a brief, online stigma-reduction intervention that pairs clinical training on buprenorphine with exposure to 1) other rural PCPs who prescribe buprenorphine and 2) patients who received buprenorphine and are in sustained recovery. The Buprenorphine Prescribing Support Program (BPSP) is paired with a booster module and long-term prescribing mentorship. In this presentation, we will present the data that informed the development of the Buprenorphine Prescribing Support Program and results from a pilot clinical trial. Our long-term goal is a brief, effective stigma-reduction program that can be easily scaled to encourage widespread, appropriate buprenorphine use in rural primary care.

View Event →
Apr
8
12:00 PM12:00
Buprenorphine, Harm Reduction, MOUD, Syringes Services Program

CDIAS PSMG: Andrea Jakubowski

Low Threshold Buprenorphine: What do we know and where do we go from here?

Andrea Jakubowski, MD, MS
Montefoire

ABSTRACT:
Over two decades into the opioid overdose crisis, buprenorphine remains underutilized and inaccessible to many people with opioid use disorder. Improving accessibility and utilization requires attention to where treatment is offered and how patients are treated once they enter care. In this presentation, Dr. Jakubowski will describe: 1) principles of low-threshold buprenorphine; 2) clinical and implementation data on syringes services program (SSP)-based buprenorphine programs; 3) early findings from Dr. Jakubowski’s NIDA K23 examining implementation of long-acting injectable buprenorphine in SSP and primary care clinics; 4) description and rationale of CTN-0155: Low-Threshold Buprenorphine Treatment at Syringe Services Programs: A Type I Hybrid Effectiveness-implementation Trial.

View Event →
Sep
24
12:00 PM12:00
Substance Use Disorder, Scaling-Out, Telehealth, Buprenorphine, Retention in Care

CDIAS PSMG: Stephen Martin and Stephanie Strong

Better, Faster, Cheaper, and Scaled: Opioid Use Disorder Treatment in the Fentanyl Era

Stephen Martin, MD, EdM
Boulder Care

Stephanie Strong, CEO, Founder
Boulder Care

ABSTRACT:
Treating opioid use disorder may be described as a “strike while the iron’s hot” scenario. Treatment must occur before doubts, withdrawal, or challenging life circumstances overwhelm someone who is interested, closing the window of opportunity. Despite nationwide efforts to expand access to highly effective medications like methadone and buprenorphine, both remain underused due to a combination of regulatory and attitudinal barriers. These barriers manifest in long wait-times (a problem of timing) and treatment scarcity (a problem of scale).

View Event →
Feb
27
12:00 PM12:00
Opioid use disorders, CRAFT, Family, Buprenorphine

C-DIAS PSMG: Karen Osilla

It takes a village: Implementing a pragmatic trial to evaluate a group telehealth intervention for family members affected by opioid use disorder

Karen Osilla, PhD
Stanford University School of Medicine

ABSTRACT:
Opioid use disorder (OUD) has devastating effects on individuals, families, and communities. This presentation describes eINSPIRE (INtegrating Support Persons Into REcovery), a pragmatic randomized trial that tests the Community Reinforcement Approach and Family Training (CRAFT) intervention delivered via group telehealth therapy compared to usual care. CRAFT is an evidence-based approach for the family members or close friends (referred to as Support Persons; SPs) of individuals with a substance use disorder. Patients and SP dyads were recruited across five community health systems in Southern and Northern California that provide buprenorphine treatment and mental health services. This presentation will describe our dyadic recruitment and implementation insights on the adoption, reach, and feasibility of intervening with SPs in these settings.

View Event →